News Quantified

PBYI – puma biotechnology inc (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer [Yahoo! Finance]

Puma Biotechnology, Inc. (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer [Yahoo! Finance]

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative [Yahoo! Finance]

-5.0%

BEAT

9.4%

BEAT

-2.0%

BEAT

-5.3%

MISS

Form SCHEDULE 13G/A PUMA BIOTECHNOLOGY, INC. Filed by: ACORN BIOVENTURES, L.P.

Form SC 13G PUMA BIOTECHNOLOGY, INC. Filed by: BlackRock, Inc.

Form 10-Q PUMA BIOTECHNOLOGY, INC. For: Sep 30

Form 8-K PUMA BIOTECHNOLOGY, INC. For: Nov 07

Form SC 13G PUMA BIOTECHNOLOGY, INC. Filed by: BlackRock, Inc.

Top News Gainers

2/4 Form 4 PUMA BIOTECHNOLOGY, INC. For: Feb 03 Filed by: BRYCE RICHARD PAUL 40.3%

2/4 Puma Biotechnology Inc (NASDAQ: PBYI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 31.6%

11/7 Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 28.5%

11/7 Form 10-Q PUMA BIOTECHNOLOGY, INC. For: Sep 30 25.9%

8/8 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.900 ActVsEst 0.330 - Beat 25.3%

3/23 Form 8-K PUMA BIOTECHNOLOGY, INC. For: Mar 16 17.3%

4/18 Puma Biotechnology Inc (NASDAQ: PBYI) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 16.3%

12/2 Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries 13.1%

4/3 Form 4 PUMA BIOTECHNOLOGY, INC. For: Apr 02 Filed by: AUERBACH ALAN H 9.7%

3/3 Form 4 PUMA BIOTECHNOLOGY, INC. For: Mar 02 Filed by: AUERBACH ALAN H 9.4%

Top News Decliners

5/9 Puma Biotechnology Reports First Quarter 2019 Financial Results -41.8%

10/8 Puma Biotechnology Inc (NASDAQ: PBYI) was downgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "sell" rating. They now have a $8.00 price target on the stock, down previously from $24.00. -18.8%

3/14 Puma Biotechnology Inc (NASDAQ: PBYI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -16.0%

12/2 Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer -14.3%

5/1 Puma Biotechnology Inc (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock. -9.7%

9/25 Puma Biotechnology to Present at Cantor Global Healthcare Conference -9.3%

5/10 Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.2%

2/20 Form 8-K PUMA BIOTECHNOLOGY, INC. For: Feb 20 -9.0%

11/13 Form 3 PUMA BIOTECHNOLOGY, INC. For: Nov 12 Filed by: Miller Ann Calby -9.0%

4/27 Form DEF 14A PUMA BIOTECHNOLOGY, INC. For: Jun 09 -8.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day